SLC5A2 and diabetes mellitus: In addition, current major Guidelines for diabetes recommend the use of metformin and sodium-glucose co-transporter 2 (SGLT2) inhibitors for patients with DM and cardiac complications, as they have showed better outcomes and improvements, however, studies to investigate the concurrent use of metformin or SGLT2 with warfarin and/or DOACs are lacking, and we urge for future studies to investigate this association.